The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

Tom Keith-Roach, president of AZ's UK business, said: "The UK approval of Trixeo Aerosphere with the [new] propellant marks a ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma.

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...

(Alliance News) - AstraZeneca PLC on Monday announced that its medicine Trixeo Aerosphere has been approved by the UK Medicines & Healthcare Products Regulatory Agency with "an innovative, ...

In addition, he took his controller medication therapies, including budesonide-formoterol, 160-4.5 micrograms, two puffs twice a day. Tiotropium bromide, 1.25 micrograms, two puffs daily ...